Bristol Myers Squibb Marks a Decade of GAAP Progress, Expanding Efforts to Advance Equity in Multiple Myeloma Care
Bristol Myers Squibb Strengthens and Expands Commitment to Advancing Equitable Care in Multiple Myeloma as GAAP Initiative Reaches Ten Years Bristol Myers Squibb (NYSE: BMY), a recognized leader in oncology,…
Lilly to Acquire Centessa Pharmaceuticals to Strengthen Pipeline in Sleep-Wake Disorder Treatments
Lilly Announces Acquisition of Centessa Pharmaceuticals to Expand Pipeline in Sleep-Wake Disorder Treatments Eli Lilly and Company and Centessa Pharmaceuticals plc have announced a definitive agreement under which Lilly will…
Nominations Begin for the Second Annual Thomas J. Fogarty Prize Celebrating Transformative Medtech Innovations
Submissions Open for the Second Annual Thomas J. Fogarty Prize Recognizing Breakthrough Medtech Innovations Nominations are set to open on April 2, 2026, for the second annual Thomas J. Fogarty…
LumaCyte’s Analytical Method Recognized in Newly Released ISO Global Standard for Viral Vector Quantification
LumaCyte’s Analytical Method Recognized in Newly Issued ISO Global Standard for Viral Vector Quantification LumaCyte has announced a significant milestone for its proprietary analytical technology, revealing that its approach has…
Bayer Unveils U.S. Leadership Transition in Pharmaceuticals’ Worldwide Markets Division to Drive Future Growth
Bayer Implements U.S. Leadership Restructuring in Pharmaceuticals’ Worldwide Markets to Accelerate Growth Potential Bayer has announced a significant leadership transition within its Pharmaceuticals division, signaling a strategic move to accelerate…
Parse Biosciences, a QIAGEN Company, Introduces FFPE-Compatible Barcoding Technology for Whole Transcriptome Single-Cell Analysis
Introduces FFPE-Compatible Barcoding Innovation Enabling Whole Transcriptome Single-Cell Analysis Parse Biosciences, a subsidiary of QIAGEN and a recognized leader in scalable single-cell sequencing technologies, has announced the commercial launch and…
Omeros Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
Omeros Corporation Releases Fourth Quarter and Full-Year 2025 Financial Results Omeros Corporation has reported a transformative set of financial and operational results for the fourth quarter and full year ended…
GE HealthCare Urges Shareholders to Decline Potemkin Limited’s “Mini-Tender” Offer
GE HealthCare Advises Shareholders to Reject Potemkin Limited’s “Mini-Tender” Proposal GE HealthCare Technologies Inc. has issued a formal response to an unsolicited “mini-tender” offer made by Potemkin Limited, urging its…
Tanner Pharma Group and Biodexa Introduce Global Early Access Initiative for Patients with FAP
Tanner Pharma Group and Biodexa Introduce Global Early Access Initiative for Patients with Familial Adenomatous Polyposis (FAP) Tanner Pharma Group, a globally recognized provider of specialty medicine access solutions, has…
Sub-Q Bionics Secures $1.5 Million Pre-Seed Funding to Accelerate Innovative Lymphedema Treatment Solution
Sub-Q Bionics Raises $1.5 Million Pre-Seed Round to Accelerate Development of Next-Generation Lymphedema Care Technology Sub-Q Bionics, an emerging innovator in the medical device space, has taken a significant step…
WuXi Biologics Secures CDMO Leadership Awards for Ninth Straight Year
WuXi Biologics Earns CDMO Leadership Awards for the Ninth Straight Year WuXi Biologics has once again reinforced its leadership position in the global biologics outsourcing sector, announcing that it has…
Kerendia™ Receives EU Approval for New Indication in Adults with Heart Failure and LVEF ≥40%
Kerendia™ Receives EU Approval for Expanded Use in Adults with Heart Failure and LVEF ≥40% Bayer has achieved a major regulatory milestone with the approval of Kerendia (finerenone) by the…